Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: A transcranial magnetic stimulation study

Clinical Neurophysiology

Volumn 111, Issue 7, 2000, Pages 1198-1202

  Strafella, A P ^a   Valzania, F ^a   Nassetti, S A ^a   Tropeani, A ^a   Bisulli, A ^a   Santangelo, M ^a   Tassinari, C A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Cortical excitability; Levodopa; Parkinson's disease; Pergolide; Transcranial magnetic stimulation

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; DOPAMINE RECEPTOR; PERGOLIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FACILITATION; HUMAN; LONG TERM EXPOSURE; MOTOR CORTEX; NERVE CELL EXCITABILITY; NERVE CELL INHIBITION; NEUROPHYSIOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECEPTOR DOWN REGULATION; TRANSCRANIAL MAGNETIC STIMULATION;

AGED; ANALYSIS OF VARIANCE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTRIC STIMULATION; HUMANS; LEVODOPA; MIDDLE AGED; MOTOR CORTEX; NEURAL INHIBITION; PARKINSON DISEASE; PERGOLIDE; REACTION TIME; SENSORY THRESHOLDS; SEVERITY OF ILLNESS INDEX; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 0034237299     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-2457(00)00316-3     Document Type: Article

References (22)

1. Calon F., Goulet M., Blanchet P.J., Martel J.C., Piercey M.F., Bédard P.J. Di Paolo. T. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABA A receptors in the striatopallidal complex. Brain Res. 680:1995;43-52.
2. Cedarbaum J.M., Clark M., Toy L.H., Green-Parsons A. Sustained-release (+)- PHNO[MK-458(HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as long-acting formulation. Mov Disord. 5:(4):1990;298-303.
3. Chen R., Samii A., Canos M., Wassermann E.M., Hallett M. Effects of phenytoin on cortical excitability in humans. Neurology. 49:1997;881-883.
4. Hanajima R., Ugawa Y., Terao Y., Ogata K., Kanazawa I. Ipsilateral corticocortical inhibition of the motor cortex in various neurological disorders. J Neurol Sci. 140:1996;109-116.
5. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology. 35:1985;296-299.
6. Jenner P., Boyce S., Marsden C.D. Receptor changes during chronic dopaminergic stimulation. J Neural Transm. 27:1998;161-175.
7. Kujirai T., Caramia M.D., Rothwell J.C., Day B.L., Thompson P.D., Ferbert A., Wroe S., Asselman P., Marsden C.D. Corticocortical inhibition in human motor cortex. J Physiol. 471:1993;501-519.
8. Lieberman A.N., Goldstein M., Leibowitz M., Gopinathan G., Neophytides A., Hiesiger E., Nelson J., Walker R. Long-term effect of pergolide. Neurology. 33:(Suppl 2):1983;112.
9. Mouradian M.M., Juncos J.L., Fabbrini G., Chase T.N. Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol. 22:1987;475-479.
10. Mouradian M.M., Juncos J.L., Fabbrini G., Schlegel J., Bartko J.J., Chase T.N. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol. 24:1988;372-378.
11. Nakamura H., Kitagawa H., Kawaguchi Y., Tsuji H. Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. J Physiol. 498:(3):1997;823-871.
12. Priori A., Berardelli A., Inghilleri M., Accornero N., Manfredi M. Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial magnetic stimulation in normal subjects, patients with Parkinsons's disease and drug-induced parkinsonism. Brain. 117:1994;317-323.
13. Ridding M.C., Inzelberg R., Rothwell J.C. Changes in excitability of motor cortical circuitry in patients with parkinson's disease. Ann Neurol. 37:1995;181-188.
14. Ridding M.C., Sheean G., Rothwell J.C., Inzelberg R., Kujirai T. Changes in the balance between motor cortical excitation and inhibition in focal task specific dystonia. J Neurol Neurosurg Psychiatry. 59:1995;493-498.
15. Watts R.L. The role of dopamine agonists in early Parkinson's disease. Neurology. 49:(Suppl 1):1997;S34-S48.
16. Ziemann U., Bruns D., Paulus W. Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation. Neurosci Lett. 208:1996;187-190.
17. Ziemann U., Lonnecker S., Steinhoff B.J., Paulus W. The effect of lorazepam on the motor cortical excitability in man. Exp Brain Res. 109:1996;127-135.
18. Ziemann U., Lonnecker S., Steinhoff B.J., Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol. 40:1996;367-378.
19. Ziemann U., Rothwell J.C., Ridding M.C. Interaction between inhibition and facilitation in human motor cortex. J Physiol. 496:(3):1996;873-881.
20. Ziemann U., Bruns D., Paulus W. Impaired motor cortex inhibition in patients with Parkinson's disease and other parkinsonian syndromes. A transcranial magnetic stimulation study. Mov Disord. 11:(Suppl 1):1996;72.
21. Ziemann U., Tergau F., Bruns D., Baudewig J., Paulus W. Changes in human motor cortex excitability induced by dopaminergic and antidopaminergic drugs. EEG Clin Neurophysiol. 105:1997;430-437.
22. Ziemann U., Paulus W., Rothenberger A. Decreased motor inhibition in Tourette syndrome. Evidence from transcranial magnetic stimulation. Am J Psychiatry. 154:1997;1277-1284.